Evotec SE EVO
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Evotec SE (EVO) is a healthcare company listed in the US with a market value of about $562M. In the twelve months to September 30, 2026 it had revenue of $792M and net income of -$199M, a net margin of -25.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.
About Evotec
Evotec is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $502M in 2019 to $869M in 2025, growth of about 9.6% a year. It was profitable in 3 of the last 7 years in our data.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $792M | $869M | $828M | $863M | $801M | $700M | $615M | $502M |
| Net income | -$199M | -$114M | -$204M | -$93M | -$187M | $244M | $8M | $43M |
| Free cash flow | -$151M | -$101M | -$103M | -$195M | $26M | $9M | -$67M | $12M |
| EPS (diluted) | $-0.56 | $-0.32 | $-0.57 | $-0.26 | $-0.53 | $0.69 | $0.02 | $0.12 |
| Net margin | -25.2% | -13.1% | -24.6% | -10.7% | -23.4% | 34.9% | 1.2% | 8.6% |
| ROIC | — | — | -9.1% | -2.4% | 1.1% | 2.1% | 3.6% | 8.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Evotec stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Evotec pay a dividend?
Not currently.
Is Evotec a good stock to buy?
We do not give buy or sell advice. Evotec scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.